Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.

2022 Startups to Watch
stats here
Related Posts on Startland News
Autotech startup VINCUE secures Series B with fleet of industry investors, innovators
A downtown Kansas City-headquartered startup’s first major institutional investment is expected to enable the company to scale operations, advance its product roadmap, and meet increasing market demand, its co-founders said Tuesday. VINCUE — an end-to-end inventory lifecycle solution for retail automotive dealerships and one of Startland News’ Kansas City Startups to Watch in 2022 —…
Bottom line, their ‘Grief Forecast’ calculates how much ignoring employees’ loss will cost a company
An Overland Park-based HRtech startup has added new tools to its B2B software platform that equips corporate leaders with the necessary knowledge to support grieving employees. This summer, Workplace Healing launched its Grief Forecast, a free resource that calculates how much a company will lose from its annual bottom line by not properly supporting employees…
Sunflower fest opens at KC Wine Co as popular pumpkin patch grows into year-round destination
Transforming from a Jurassic farm to a winter wonderland, the green thumbs at KC Pumpkin Patch have grown their niche as a year-round destination in rural southwest Johnson County. Next set to bloom: a sunflower-rich selfie oasis on the prairie (with wine). “We loved having folks come for the fall [pumpkin patch] season, but people…
Hemp could be the next superfood: How one state-backed company is connecting farmers to retailers now
Startland News’ Startup Road Trip series explores innovative and uncommon ideas finding success in rural America and Midwestern startup hubs outside the Kansas City metro. AUGUSTA, Kansas — A Kansas company specializing in agricultural and industrial hemp hopes that a collaborative, educational approach in a burgeoning industry will benefit farmers, the environment, and end users…

